**[192] THE SIGHTDX PLATFORM FOR COMPUTER VISION DIAGNOSTICS**

**Seth Salpeter1, 1 Sight Diagnostics**

**ABSTRACT TEMPLATE for Company Presentations**

The maximum number of words for this abstract is 300 words.
You may delete the section instructions, leaving only the bolded bullet title.

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

 **Answers should not exceed 60** **words per question**

* **Investment Rational**
Briefly describe the company's technology or therapeutic focus.  The market opportunity, progress made to date key partnerships or joint ventures. Management strengths

SightDx has created the Parasight platform, an image-processing device for blood analysis that combines cutting edge computer‐vision algorithms, custom low‐cost hardware and novel blood‐preparation techniques to detect malaria in a rapid, reliable and completely automated fashion.

* **Business Strategy**
Briefly describe how the company will apply its core technology,
Generate near-term and long term revenues

The company aims to place the malaria detection device in markets with high malaria burden, specifically targeting hospitals, pathology labs and blood banks. These locations that perform high volumes of tests will be ideal consumers for purchasing our system, as we intend to set up a "gilette" revenue model where most of the revenues are based on the consumable.

* **Core Technology**
What is the technology, its uniqueness and its value proposition

Our computer-vision software can identify the visual differences between healthy and parasite-infected blood, while scanning a greater quantity of blood with more consistency than a human miscroscopist, thus minimizing the limit of detection. The technology is more accurate and quicker than the current diagnostic platforms.

* **Product Profile/Pipeline**
Describe companies’ product/pipelines, current status and market potential. Discuss milestones, potential collaboration and partnership

The company has placed 30 devices in 2015 and is projecting the placement of 100 devices in 2016. We have recently signed a distribution agreement with Becton Dickinson in India.

* **What's Next?**
R&D
Preclinical / Clinicals
Organizational plans
Financial plans

Our next application is for point of care complete blood count testing in western markets.